Victory Capital Management Inc. Has $186.68 Million Stock Position in Amgen Inc. $AMGN

Victory Capital Management Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 34.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 661,514 shares of the medical research company’s stock after selling 354,439 shares during the period. Victory Capital Management Inc.’s holdings in Amgen were worth $186,679,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of AMGN. Sequoia Financial Advisors LLC increased its holdings in shares of Amgen by 2.3% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares during the period. Atlantic Union Bankshares Corp raised its holdings in shares of Amgen by 165.0% during the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after acquiring an additional 6,627 shares in the last quarter. Davis Capital Management acquired a new position in Amgen in the 3rd quarter worth about $1,841,000. D.A. Davidson & CO. increased its position in Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after purchasing an additional 6,222 shares during the last quarter. Finally, Global Wealth Management Investment Advisory Inc. raised its stake in shares of Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after purchasing an additional 4,699 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $377.00 on Wednesday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $203.23 billion, a price-to-earnings ratio of 26.49, a P/E/G ratio of 3.83 and a beta of 0.45. The company’s fifty day moving average is $350.89 and its two-hundred day moving average is $321.17. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s payout ratio is presently 70.84%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AMGN. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price for the company. in a research note on Tuesday, January 20th. Scotiabank began coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price on the stock. DZ Bank upped their price target on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. The Goldman Sachs Group increased their price target on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Finally, Piper Sandler boosted their price objective on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen has an average rating of “Moderate Buy” and a consensus price target of $351.76.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.